Development↦Biobanking↦Safety↦Risk-Based Approach
What is it? Why is it important?
A risk-based approach is a decision-making process that takes into consideration ways to identify, evaluate, prioritise, and control risks associated with some undertaking, such as a biobank.
Potential safety-risks related to the management of a biobank can include:
- The governance of the Biobank (e.g. biobanking processes, responsibilities, staff resources and training, applicable laws and guidelines)
- The management of biobanking facilities and materials (e.g. work/storage space, biobanking equipment such as freezers, pipettes, labs, consumables)
- Staff and donor safety
- The agreement and documentation of donor consent
- Handling of Biological Material (BM) (e.g. sample workflow)
Once risks are identified and assessed, applicable risk control-measures are implemented and checked for ongoing efficacy and applicability (e.g. risk review)
What do I need to do?
Familiarise yourself with how to identify and assess potential biobanking risks. Based on risk identification:
- Evaluate:
- The likelihood of risk occurrence (probability)
- Expected impact of risk (severity) (e.g. decrease quality of BM, donor right, faulty analytical results)
- Define risk control-measures
- Communicate and train staff on risk management
- Perform risk-reviews in order to check the ongoing efficacy and applicability of risk control-measures, including the potential occurrence of new risks (e.g. new equipment, new staff, new procedures)
- Document your risk management strategy in a Risk Assessment Form
Regarding safety breaches:
- Ensure they are immediately notified, communicated, and documented (e.g. RAF)
- Perform a root cause-analysis and define control-measures to prevent its re-occurrence
- Train staff
During the ongoing management of your biobank include the documentation and handling of non-conformities (NC) in your risk-based approach.
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
The Swiss Biobanking Platform (SBP) can provide you with support on this topic.
SBP Documents
SOPs, Forms and Templates – see in particular
- Risk management SOP
- Annex
External Links
Swissethics – see in particular
- Topics / Biobanks and data registries
References
ICH GCP E6(R2) – see in particular guideline
- 5.0 for quality management
ISO 31000 Risk Management (access liable to costs) – see in particular section
- Risk management: Principles and guidelines
ISO 20387:2018 Biotechnology - Biobanking (access liable to cost) - General Requirements for Biobanking – see in particular section
- 8.5 Actions to address risks and opportunities
Swiss Law
HRA – see in particular article and chapter
- Art. 12 Risks and burdens
- Chapter 3 Requirements for research involving vulnerable persons